Chinese vaccines against COVID-19. The tiger prepares to jump …

Chinese companies have long been leaders in the vaccine race. The shortened list of intermediate finishes to which they came first is as follows:

initiation of vaccine trials in volunteers
publication of successful results of phase 1-2 clinical trials
start of vaccination against COVID-19 “high risk groups”
start of phase 3 clinical trials
massive use of vaccination against COVID-19

 

Prior to Phase 3 clinical trials of their vaccines, Chinese developers published their data in leading international scientific journals. However, by entering the first phase 3 clinical trials, Chinese developers ceded leadership. I do not exclude that the resulting “lag” is temporary. But it is unfortunate that the degree of openness of information about the results of clinical trials of vaccines has decreased – the results of phase 3 have not been published, and recent reports on their protective efficacy have not yet been detailed.

 

To be fair, it must be said that Chinese researchers are testing their vaccines in less “comfortable” conditions than other developers. China has carried out anti-epidemic measures fantastically effectively and since April the incidence of COVID-19 in the country has been practically zero. At such a low rate of SARS-CoV-2 infection, it is impossible to conduct Phase 3 clinical trials of COVID-19 vaccines. Working in other jurisdictions and cultural environments is much more difficult than working at home, not to mention reducing the “administrative resource”. However, Chinese developers have been able to launch clinical trials in 15 countries on various continents.Поділитися цим:

0

Автор публікації

Офлайн 1 місяць

Amir0406

0
Коментарі: 0Публікації: 20Реєстрація: 18-01-2021

You may also like...

Залишити відповідь

Войти с помощью: 

Ваша e-mail адреса не оприлюднюватиметься.

Авторизація
*
*
Войти с помощью: 
Реєстрація
*
*
*
Войти с помощью: 
Генерація паролю